Blastomycosis¶
Chapter 220 | Part 5: Infectious Diseases
KEY CLINICAL POINTS¶
- Blastomycosis is a pyogranulomatous fungal infection caused by Blastomyces species, primarily affecting immunocompetent individuals but also immunocompromised hosts.
- Clinical presentation varies from asymptomatic to severe pneumonia, disseminated disease, and CNS involvement; diagnosis requires high clinical suspicion due to mimicry of other infections.
- Treatment guidelines recommend amphotericin B for severe cases, followed by triazoles (e.g., itraconazole) for 6–12 months; CNS involvement requires prolonged antifungal therapy.
- Geographic distribution includes North America, Africa, and Asia; risk factors include soil exposure, immunosuppression, and endemic region residency.
- Genetic factors (e.g., IL-6 polymorphisms in Hmong populations) may contribute to increased susceptibility to blastomycosis.
1. DEFINITION & OVERVIEW¶
Blastomycosis is a systemic fungal infection caused by Blastomyces species, characterized by pyogranulomatous inflammation. It is a primary fungal infection affecting individuals with intact or impaired immune systems. The disease can present as pulmonary, cutaneous, or disseminated infection, with the latter involving organs such as the skin, bone, brain, and genitourinary system.
Table 220-1: Treatment Guidelines for Blastomycosis¶
| Patient Group | Recommended Therapy | Duration |
|---|---|---|
| Immunocompetent, mild/moderate pulmonary | Itraconazole | 6–12 months |
| Immunocompetent, severe pulmonary/disseminated | Lipid AmB (7–14 days) + Itraconazole | 6–12 months |
| CNS involvement | Lipid AmB (4–6 weeks) + Voriconazo le/Itraconazole/Fluconazole | ‡12 months |
| Osteomyelitis | Itraconazole | ‡12 months (surgical debridement may be required) |
| Immunosuppressed (e.g., transplant recipients) | Lipid AmB (7–14 days) + Itraconazole | 12 months |
1.1 Pathogenesis¶
Blastomyces exhibits thermal dimorphism, switching between hyphal forms in soil (22–25°C) and yeast forms in host tissues (37°C). The yeast form evades immune defenses via upregulation of virulence factors like BAD1 (Blastomyces adhesin 1) and downregulation of host immune responses. Genetic polymorphisms (e.g., IL-6) may predispose certain populations (e.g., Hmong) to infection.
1.2 Clinical Spectrum¶
Pulmonary disease is most common (69–93% of cases), presenting as pneumonia, ARDS, or asymptomatic infection. Disseminated disease (15–48% of cases) involves skin, bone, CNS, or genitourinary systems. Coccidioidal meningitis is a challenging complication requiring prolonged antifungal therapy.
2. EPIDEMIOLOGY¶
Blastomycosis is endemic in North America (Mississippi River basin, Great Lakes, St. Lawrence River), Africa, and Asia. Annual incidence ranges from 0.11 to 2.17 cases/100,000 in traditional endemic areas. Hyperendemic regions (e.g., Vilas County, Wisconsin) report rates up to 117/100,000. Risk factors include soil exposure, immunosuppression, and travel to endemic regions. Hmong populations show increased risk due to genetic factors (IL-6 polymorphisms).
2.1 Demographics¶
Most cases occur in adults, with higher incidence in older individuals (Medicare beneficiaries: 0.7/100,000 annually). Disseminated disease is more common in immunocompromised hosts (e.g., transplant recipients, HIV patients).
2.2 Geographic Distribution¶
Traditional endemic areas in North America include the Mississippi River basin, Great Lakes, and St. Lawrence River regions. In Canada, endemic regions include Saskatchewan, Manitoba, Ontario, and Quebec. Africa and Asia have sporadic cases, with multiple Blastomyces species identified.
3. ETIOLOGY & PATHOPHYSIOLOGY¶
Blastomycosis is caused by the Blastomyces species complex, including B. dermatitidis, B. gilchristii, B. helicus, and others. Thermal dimorphism allows growth as hyphae in soil and yeast in host tissues. Virulence factors include BAD1 (adhesin), resistance to oxidative stress, and modulation of host immune responses. Genetic polymorphisms (e.g., IL-6) may predispose certain populations to infection.
3.1 Species Diversity¶
Blastomyces species include B. dermatitidis (most common), B. gilchristii (glaciated regions), B. helicus (western U.S., Canada), and others (B. percursus, B. emzantsi). B. helicus is associated with fungemia and high mortality in immunosuppressed hosts.
3.2 Thermal Dimorphism¶
Blastomyces grows as hyphae in soil (22–25°C) and converts to yeast at 37°C. This transition is regulated by temperature, cysteine uptake, and signaling pathways (e.g., DRK1, HOG pathway). Yeast form evades phagocytosis and upregulates virulence factors.
4. CLINICAL FEATURES¶
Pulmonary blastomycosis presents as pneumonia, ARDS, or asymptomatic infection. Disseminated disease involves skin, bone, CNS, or genitourinary systems. Coccidioidal meningitis is a severe complication requiring prolonged antifungal therapy. Clinical features include fever, cough, hemoptysis, and extrapulmonary manifestations (e.g., skin ulcers, osteomyelitis).
4.1 Pulmonary Manifestations¶
69–93% of cases present with pulmonary symptoms: fever, cough, dyspnea, hemoptysis. Radiographic findings include lobar consolidation, nodules, cavitary disease, or miliary patterns. ARDS occurs in 4–15% of patients with high mortality (40–89%).
4.2 Disseminated Disease¶
15–43% of cases involve extrapulmonary sites: skin (papules/ulcers), bone (osteomyelitis), CNS (meningitis/abscesses), or genitourinary system. Dissemination is more common in immunocompromised hosts and those with prolonged pulmonary symptoms.
5. DIFFERENTIAL DIAGNOSIS¶
Blastomycosis must be differentiated from bacterial pneumonia, tuberculosis, lung cancer, histoplasmosis, coccidioidomycosis, and other fungal infections. Clinical clues include unresponsive pneumonia, extrapulmonary manifestations, and environmental exposure to endemic regions. Skin lesions may mimic sarcoidosis, pyoderma gangrenosum, or skin cancer.
5.1 Mimicking Conditions¶
Common differentials include community-acquired pneumonia, tuberculosis, malignancy, and other dimorphic fungal infections (e.g., Histoplasma, Coccidioides). Skin lesions may resemble cutaneous malignancies or granulomatous diseases.
5.2 Diagnostic Clues¶
Environmental risk factors (soil exposure), travel to endemic regions, and persistent respiratory symptoms unresponsive to antibiotics are critical for diagnosis. Family history of blastomycosis may also be relevant.
6. INVESTIGATIONS & DIAGNOSIS¶
Diagnosis requires a high index of suspicion. Diagnostic methods include direct microscopy (broad-based budding yeast), fungal cultures, antigen testing (galactomannan), and serology (BAD1 antibodies). Imaging (chest X-ray, CT) and biopsy may be required for confirmation.
6.1 Diagnostic Tests¶
Direct microscopy: Calcofluor, KOH, or Papanicolaou stains reveal broad-based budding yeast (4–29 µ m). Antigen testing (urine/blood) detects galactomannan with 85–93% sensitivity for urine. Serology (BAD1 antibodies) has 87% sensitivity and 94–99% specificity.
6.2 Imaging and Biopsy¶
Chest imaging shows lobar consolidation, nodules, or cavitary disease. Biopsy of skin, bone, or lung tissue reveals pyogranulomatous inflammation with yeast forms. Histopathology confirms diagnosis.
7. MANAGEMENT & TREATMENT¶
Treatment depends on disease severity and immune status. Mild pulmonary disease is treated with itraconazole for 6–12 months. Severe cases require lipid AmB induction followed by triazole therapy. CNS involvement requires prolonged antifungal therapy. Osteomyelitis requires ≥ 12 months of antifungal treatment.
7.1 Antifungal Therapy¶
Lipid AmB (7–14 days) for severe pulmonary or disseminated disease. Itraconazole (200 mg/day) for 6–12 months. Voriconazole or fluconazole for CNS involvement. Osteomyelitis requires ≥ 12 months of therapy.
7.2 Special Considerations¶
Immunosuppressed patients (e.g., transplant recipients) require 7–14 days of lipid AmB followed by 12 months of itraconazole. Pregnancy requires careful monitoring; amphotericin B is preferred over triazoles. Hmong patients may require prolonged therapy due to genetic factors.
8. PROGNOSIS & COMPLICATIONS¶
Mortality is high in severe cases (40–89% for ARDS) and in CNS involvement. Disseminated disease has a 15–48% incidence. Complications include respiratory failure, meningitis, osteomyelitis, and secondary bacterial infections. Delayed diagnosis increases mortality and morbidity.
8.1 Mortality¶
ARDS mortality: 40–89%. CNS involvement mortality: 15–30% with relapse after discontinuation. Disseminated disease mortality: 15–48% in immunocompromised hosts.
8.2 Long-Term Outcomes¶
Patients with disseminated disease require prolonged antifungal therapy ( ≥ 12 months). Relapse occurs in 15–30% after treatment discontinuation. Osteomyelitis may require surgical debridement.
9. SPECIAL CONSIDERATIONS¶
Pregnancy: Blastomycosis is uncommon but may present as pneumonia or disseminated disease. Antifungal therapy should be initiated promptly. Immunocompromised hosts (e.g., transplant recipients, HIV patients) require aggressive treatment. Hmong populations have increased risk due to genetic factors (IL-6 polymorphisms).
9.1 Pregnancy¶
Blastomycosis in pregnancy is rare, typically diagnosed in the second or third trimester. Treatment with amphotericin B is preferred over triazoles. Neonatal transmission is rare but possible via transplacental route or aspiration.
9.2 Genetic Predisposition¶
Hmong populations show increased risk due to IL-6 polymorphisms reducing IL-17 production, impairing innate immune responses. This may explain higher incidence in endemic regions.
10. KEY POINTS & CLINICAL PEARLS¶
- Blastomycosis is a systemic fungal infection caused by Blastomyces species, primarily affecting immunocompetent hosts. 2. Diagnosis requires high clinical suspicion due to mimicry of other infections. 3. Treatment guidelines recommend amphotericin B for severe cases, followed by triazoles for 6–12 months. 4. Disseminated disease and CNS involvement require prolonged antifungal therapy. 5. Hmong populations have increased risk due to genetic factors (IL-6 polymorphisms). 6. Early diagnosis and treatment are critical to prevent mortality and complications.